The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 1 week back · Material filings: 447 · All filings: 661

Material

Monday 9 Nov86 filings read · 86 material

  • 8-KFiled 9 Nov 2026All industries

    Bain Capital Specialty Finance, Inc.BCSF

    8-K · Items 2.02, 5.02, 8.01 — Results of operations

    Q3 2026 results show 10.3% annualized NII yield on equity with stable portfolio health (3.3% non-accrual). Board appointed independent director Amrit Kanwal. Q4 dividend declared at $0.42/share. Credit facility increased to $955M.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Banks

    Green Dot CorpGDOT

    8-K · Item 2.02 — Results of operations

    Recognition: Watch 44 → Watch 40Value: Very strong 85 → Balanced 50

    Market attention has faded.

    The shares became dearer on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Virtus Investment Partners, Inc.VRTS

    8-K · Item 2.02 — Results of operations

    Q3 2026 earnings declined 30% YoY to $3.26 diluted EPS. Net outflows of $6.1B, AUM down 16% YoY to $141.4B. Revenue fell 9% YoY; operating income dropped 27%. Adjusted EPS of $5.86 down 20% YoY.

    Value: Watch 42 → Watch 37Gap High · 30 → Medium · 16

    The shares became dearer on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    H&R Block IncHRB

    8-K · Item 2.02 — Results of operations

    Recognition: Balanced 51 → Balanced 46

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Ceco Environmental CorpCECO

    8-K · Item 2.02 — Results of operations

    CECO reported record Q3 2026 results with orders up 234%, backlog up 205%, and Adjusted EBITDA up 202%. Company raised 2026 orders guidance to >$2.5B and introduced 2027 outlook projecting 60%+ revenue growth and 130%+ EBITDA growth, reflecting successful Thermon acquisition integration.

    Gap Very high · 75 → Very high · 79

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Tidewater IncTDW

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $360.4M exceeded expectations; day rates increased 3.7% sequentially to $23,775/day with leading-edge rates up 12.5%. Company raised 2026 guidance and initiated strong 2027 guidance ($1.70–$1.75B revenue, 51–53% margin). WSUT acquisition closed.

    Recognition: Watch 43 → Balanced 48Value: Balanced 57 → Balanced 50Gap Medium · 23 → High · 33

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Office Properties Income TrustOPI

    8-K · Item 2.02 — Results of operations

    OPI reported Q3 2026 net loss of $45.8M ($2.09/share) despite 14.8% YoY same-property NOI growth. Company is divesting 58 properties (5.2M sq ft) with 76.9% occupancy, refinanced debt, and ended quarter at 88.8% occupancy.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Harrow, Inc.HROW

    8-K · Item 2.02 — Results of operations

    Q3 2026 record revenue of $99.3M (+39% YoY), GAAP net income $9.8M vs. prior loss. Branded revenue up 62% YoY. TYRVAYA acquisition completed. Full-year revenue guidance reaffirmed at $350–365M; Adjusted EBITDA guidance reduced to >$40M from $80–100M.

    Recognition: Watch 42 → Balanced 46Value: Watch 41 → Watch 44

    More of the market is starting to notice.

    The shares became cheaper on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Bally's CorpBALY

    8-K · Item 2.02 — Results of operations

    Bally's reported Q3 2026 preliminary consolidated revenue of $807.6M, up 21.7% YoY. Key drivers: Intralot B2C +22.8%, North America Interactive +25.6%, Casinos & Resorts +3.2%. Closed $400M Bronx project financing with $160M additional available.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Rackspace Technology, Inc.RXT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue declined 9.3% YoY to $609M. Public Cloud revenue fell 17.2% YoY. Despite raising full-year revenue guidance by $35M, the company reported net loss of $54M and increased capex to $104M, signaling operational headwinds.

    News flow: Balanced 48 → Balanced 45Recognition: Watch 37 → Watch 30Value: Balanced 45 → Watch 34

    The filings read less positively.

    Market attention has faded.

    The shares became dearer on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Paysign, Inc.PAYS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $30.8M (+43% YoY) driven by pharma affordability growth (109.8% increase). Operating margin tripled to 23.8%. Company raised full-year 2026 guidance for gross margin, net income, EPS, and Adjusted EBITDA despite announced loss of 113 plasma centers.

    News flow: first measured — Balanced 51Recognition: Strong 67 → Balanced 60Gap first measured: Medium · 10

    AIR measured this for the first time; no change to report.

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Ur-Energy IncURG

    8-K · Item 2.02 — Results of operations

    Q3 2026 shows 67% YTD sales increase and 26% captured-pound growth. Lost Creek and Shirley Basin ramping; exploration accelerating. Cash costs remain low at $40.40/lb. Inventory deferrals manage near-term delivery timing.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    WEBTOON Entertainment Inc.WBTN

    8-K · Item 2.02 — Results of operations

    WEBTOON reported Q3 2026 revenue of $362.8M (down 4.0% YoY; up 0.2% constant currency), net loss of $7.5M, and Adjusted EBITDA of $2.2M. Results within guidance. Company guides Q4 2026 constant currency revenue growth of 9-12% and expects return to double-digit growth.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    USA Rare Earth, Inc.USAR

    8-K · Item 2.02 — Results of operations

    USA Rare Earth reported Q3 2026 results with multiple operational milestones: Serra Verde Stage 1 completed on time/budget with commercial MREC shipments begun; first NdFeB magnet sales from Stillwater facility; rare earth oxide samples produced; Blacksburg facility groundbreaking ($1.2B investment); $1.2B cash position.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Zymeworks Inc.ZYME

    8-K · Item 2.02 — Results of operations

    Zymeworks raised 2026 revenue guidance to $337–351M (from $278–292M) and Adjusted EBITDA to $176–190M (from $114–128M). Ziihera received FDA approval for first-line GEA, generating $250M milestone. Roche collaboration for ZW209 announced with up to $813M in potential payments.

    Recognition: Strong 71 → Strong 68Gap Very high · 77 → Very high · 82

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026All industries

    Lineage, Inc.LINE

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show revenue decline of 1.2%, GAAP net loss of $173M, adjusted EBITDA down 7.0%, and AFFO per share down 14.1%. Management cites temporary headwinds from oil prices, trucking constraints, and tariff uncertainty, with guidance reduced for full-year 2026.

    Recognition: Balanced 52 → Balanced 48

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    AbCellera Biologics Inc.ABCL

    8-K · Item 2.02 — Results of operations

    AbCellera announced positive Phase 2 data for ABCL635 showing significant efficacy in vasomotor symptoms with favorable safety. Raised $200M, expanding liquidity to ~$900M. Added three new pipeline programs and achieved Phase 1 readout for ABCL575.

    Recognition: Strong 65 → Balanced 61Gap Medium · 16 → High · 27

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026All industries

    Select Water Solutions, Inc.WTTR

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 28% YoY to $412M; net income increased to $23M; Adjusted EBITDA rose 57% to $93.5M. Water Infrastructure segment hit record $110M revenue (+40% YoY). Company completed Peak Rentals divestment and closed Pilot Water acquisition post-quarter.

    Recognition: Balanced 56 → Balanced 51Value: Watch 41 → Balanced 50Gap Very high · 92 → Very high · 95

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Surgery Partners, Inc.SGRY

    8-K · Item 2.02 — Results of operations

    Surgery Partners announced amended merger agreement with HealthSpan Partners at $25/share ($6B enterprise value) following competing proposal. Q3 revenue declined 0.8% YoY; Adjusted EBITDA fell to $132.7M from $136.4M. Net loss of $21.1M. Same-facility revenue grew 6.0% but overall metrics weakened.

    Value: Balanced 55 → Balanced 47Gap Low · 9 → Medium · 21

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Neurogene Inc.NGNE

    8-K · Item 2.02 — Results of operations

    Neurogene reported Q3 2026 results with NGN-401 Rett syndrome trial on track for topline data in H2 2027. PPQ manufacturing runs expected complete by year-end 2026. Strong cash position ($359.7M) funds operations into Q1 2029. Safety profile remains favorable in 35 dosed participants.

    Gap Medium · 18 → High · 30

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Babcock & Wilcox Enterprises, Inc.BW

    8-K · Item 2.02 — Results of operations

    B&W reported Q3 2026 revenue of $291M (+109% YoY), net income $94M, EPS $0.61 (+103% YoY), and adjusted EBITDA $17.7M (+88% YoY). Backlog surged 571% to $2.5B; pipeline exceeds $16B. Issued 2027 adjusted EBITDA guidance of $125–$140M.

    Recognition: Watch 28 → Watch 34Gap Very high · 61 → Very high · 72

    More of the market is starting to notice.

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Quantum Corp /De/QMCO

    8-K · Item 2.02 — Results of operations

    Q2 FY2027 revenue grew 42.9% YoY to $89.6M with gross margin expansion to 41.0%. Non-GAAP net income $9.8M ($0.25/share) vs. prior-year loss. Record ~$100M backlog and major hyperscale Scalar i7 Raptor order secured.

    Recognition: Balanced 49 → Balanced 54Value: Watch 36 → Watch 27Gap Low · 0 → Medium · 12

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Clearway Energy, Inc.CWEN

    8-K · Item 2.02 — Results of operations

    Q3 2026 earnings exceeded prior year with $123M net income and $435M Adjusted EBITDA. Company reaffirmed 2026 guidance, initiated 2027 guidance ($520–590M CAFD), and announced three committed growth investments (Swan Solar, Honeycomb 2, Heartland) totaling ~$379M with ~$36M annual CAFD contribution.

    Gap Very high · 45 → Very high · 54

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    GeneDx Holdings Corp.WGS

    8-K · Item 2.02 — Results of operations

    GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY), with exome/genome revenue at $110.4M (+12% YoY). Volume growth of 25% YoY and 28% accession growth. Adjusted gross margin expanded to 72%, adjusted net income $8.6M. Full-year guidance maintained at $475–$490M.

    Value: Watch 26 → Watch 37

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Quantum Computing Inc.QUBT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $9.5M exceeded H1 2026 total ($9.2M), driven by acquired businesses (LSI, NuCrypt, NHanced). Company maintains $1.3B cash position and $39.1M backlog. New pharma partnership and university collaboration announced.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Ceva IncCEVA

    8-K · Item 2.02 — Results of operations

    Q3 2026: Total revenues $29.1M (+2% YoY), royalty revenues $12.7M (+18% sequentially), record AI licensing (>35% of licensing). Multi-year smartphone modem ramp ahead. Device shipments matched all-time record at 623M units.

    Gap Low · 0 → Medium · 10

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Mesa Laboratories Inc /Co/MLAB

    8-K · Item 2.02 — Results of operations

    Mesa Labs reported Q2 FY2027 results with 2.6% revenue growth, 77.6% operating income increase, and 75.3% net income growth. Company issued first full-year guidance ($250–255M revenue, $66–68M adjusted EBITDA) and announced $9.3M cost-reduction plan with $4.3M reinvestment.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Delcath Systems, Inc.DCTH

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $35.1M (+70% YoY) driven by HEPZATO KIT sales of $32.7M (+69% YoY). Net income $7.0M vs $0.8M prior year. Company raised 2026 revenue guidance to $115–117M, reflecting ≥41% HEPZATO volume growth. 33 active treatment centers; Phase 2 DELUMA trial ongoing.

    Recognition: Watch 44 → Balanced 50Gap Low · 3 → Medium · 16

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Life360, Inc.LIF

    8-K · Item 2.02 — Results of operations

    Life360 reported Q3 2026 results with 40% YoY revenue growth to $174.1M, record third-quarter Paying Circle additions (188K), and 107.7M MAU. Raised FY26 revenue guidance to $665–681M. Advertising revenue surged 250% YoY post-Nativo acquisition.

    Recognition: Watch 44 → Watch 41Gap Low · 0 → Medium · 15

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Banks

    MARA Holdings, Inc.MARA

    8-K · Item 2.02 — Results of operations

    MARA reported Q3 2026 results showing revenue decline but significant net income and EBITDA growth, $1.4B debt reduction (37% of total), FERC approval for Long Ridge power plant, Exaion's $79M GPU contract, and authorization of $500M share repurchase program.

    Value: Balanced 50 → Balanced 47

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Immunovant, Inc.IMVT

    8-K · Item 2.02 — Results of operations

    IMVT-1402 600 mg met primary endpoint in difficult-to-treat RA trial (92.5% vs 75.6% placebo, p=0.0139). Strong exploratory ACR50/ACR70 responses. Good safety profile. FDA discussions planned. Sjögren's indication deprioritized.

    Recognition: Balanced 47 → Balanced 51Gap Low · 0 → Medium · 13

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Dole plcDOLE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 3.8% to $2.4B and adjusted EBITDA rose 4.1% to $84.1M, but full-year 2026 guidance was reduced to $380–390M from ~$400M due to elevated fuel/shipping costs and adverse weather impacts on fruit supply.

    No notable change in AIR's read.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Hallador Energy CoHNRG

    8-K · Item 2.02 — Results of operations

    Hallador reported Q3 2026 results with sequential revenue growth and secured $600M construction financing for Turtle Creek 460-MW natural gas project. Forward sales increased 26% to $3.0B; targeting FID by year-end 2026 and commercial operation H2 2028.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Powerfleet, Inc.AIOT

    8-K · Item 2.02 — Results of operations

    Powerfleet reported Q2 FY2027 record revenue of $115.7M (4% sequential growth), services revenue up 7% YoY, and profit from operations of $1.4M. Company secured device financing facility with Rand Merchant Bank and launched two new AI products (Unity Foresight, Unity Asset Intelligence). Affirmed full-year guidance.

    Recognition: Watch 43 → Watch 37Gap Low · 3 → Medium · 18

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    National Energy Services Reunited Corp.NESR

    8-K · Items 2.02, 8.01 — Results of operations

    NESR reported Q3 2026 revenue of $504.7M (+70.9% YoY), net income of $34.3M (+93.5% YoY), and diluted EPS of $0.33 (+83.3% YoY). Company declared $0.10/share dividend and completed debt refinancing.

    Recognition: Watch 38 → Watch 35Gap Very high · 78 → Very high · 88

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Lincoln Educational Services CorpLINC

    8-K · Item 2.02 — Results of operations

    Lincoln Educational Services reported Q3 2026 results with strong operational performance: student starts +14.2%, revenue +12.6% to $159.2M, adjusted EBITDA +30.8% to $17.4M, net income +24.1%. Company raised full-year revenue guidance and narrowed student start guidance to 10-12%.

    Gap High · 39 → Very high · 54

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Banks

    Sharplink, Inc.SBET

    8-K · Item 2.02 — Results of operations

    Sharplink reported Q3 2026 revenue up 24% YoY to $13.5M and net income of $751.4M ($3.45/diluted share), driven by unrealized crypto gains of $676.7M and realized gains of $75.2M. ETH holdings reached ~892.7K ETH; completed $200M Lido staking allocation.

    Gap Medium · 19 → High · 29

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Plug Power IncPLUG

    8-K · Item 2.02 — Results of operations

    Plug Power reported Q3 2026 revenue of ~$201M (+13% YoY), gross margin improved ~65 percentage points to ~(3%), and record-low net cash usage of ~$28M. Material handling deployments doubled YoY; major electrolyzer orders secured including 280 MW Arcadia eFuels deal.

    Gap Medium · 18 → High · 32

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Aura Biosciences, Inc.AURA

    8-K · Items 2.02, 8.01 — Results of operations

    Phase 3 CoMpass trial fully enrolled with all 108 participants completing treatment; topline data expected 2H 2027. Established CDMO partnership with designated manufacturing capacity. Cash runway extended to 1H 2029. Organizational restructuring completed.

    Recognition: Watch 44 → Balanced 48

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Somnigroup International Inc.SGI

    8-K · Items 2.02, 8.01 — Results of operations

    SGI reported Q3 2026 record adjusted EPS of $1.04 (+9.5%), completed Leggett & Platt acquisition, improved leverage to 2.69x, and raised full-year 2026 adjusted EPS guidance to $2.85–$2.95 range (~7% growth vs. 2025).

    Value: Very strong 81 → Very strong 87Gap Very high · 76 → Very high · 80

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    HighPeak Energy, Inc.HPK

    8-K · Item 2.02 — Results of operations

    HighPeak reported Q3 2026 production above guidance (44.2 MBoe/d), generated $22.4M free cash flow, reduced debt by $30M, and announced a transformational $450M preferred equity investment with new $800M credit facility to refinance $1.2B term loan.

    Recognition: Balanced 45 → Watch 40Gap Very high · 63 → Very high · 73

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Biotech

    ImmunityBio, Inc.IBRX

    8-K · Item 2.02 — Results of operations

    ImmunityBio reported Q3 2026 net product revenue of $48.7M (53% YoY growth) and 9M revenue of $143.6M (92% YoY growth). FDA expanded ANKTIVA approval for BCG-unresponsive NMIBC papillary-only tumors; BCG-naïve trial met primary endpoint; Israel approval and first European patient treated.

    Recognition: Strong 66 → Balanced 60Gap High · 25 → High · 37

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Trump Media & Technology Group Corp.DJT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 205% YoY to $3.0M, driven by Truth API data licensing ($1.8M) and Truth+ subscriptions. S-4 merger registration with TAE declared effective; shareholder vote scheduled December 14. Balance sheet shows $2.5B total assets, $2.3B financial assets. Legal costs declined sharply.

    Gap Very high · 74 → Very high · 80

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Gladstone Investment CorporationdeGAIN

    8-K · Item 2.02 — Results of operations

    Q2 2026 net investment income fell 69.6% QoQ to $4.8M ($0.12/share) from $15.9M ($0.40/share), driven by lower investment income and higher expenses. Portfolio expanded to 31 companies with $1.43B in investments.

    Gap High · 41 → Medium · 24

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    RadNet, Inc.RDNT

    8-K · Item 2.02 — Results of operations

    RadNet reported Q3 2026 record revenue of $638.3M (+22.1% YoY) and adjusted EBITDA of $105.0M (+23.8% YoY). Company raised full-year 2026 guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow. Digital Health segment revenue grew 32.6% but EBITDA declined 11.8%.

    Value: Weak 19 → Weak 24Gap Very high · 60 → Very high · 63

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Immunome Inc.IMNM

    8-K · Item 2.02 — Results of operations

    Immunome achieved multiple clinical and regulatory milestones: varegacestat FDA PDUFA date set for April 2027 with EMA MAA validation; IM-1021 shows objective responses across B-cell lymphoma cohorts; IM-1340 IND cleared for Phase 1 initiation by year-end. Cash position of $461.6M funds operations into 2028.

    Gap Very high · 67 → Very high · 73

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Natural Gas Services Group IncNGS

    8-K · Items 2.02, 8.01 — Results of operations

    NGS reported Q3 2026 results with rental revenue up 41.9% YoY to $58.9M and Adjusted EBITDA up 42.2% to $29.6M. Company raised full-year 2026 Adjusted EBITDA guidance to $105–108M and increased quarterly dividend to $0.16/share.

    Gap Very high · 77 → Very high · 88

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Aaon, Inc.AAON

    8-K · Items 2.02, 4.02 — Results of operations

    AAON restated Q1 and Q2 2026 financial statements due to errors in revenue recognition (percent-of-completion method) and software subscription accounting. A material weakness in internal controls was identified. Despite strong Q3 operational results and raised FY2026 guidance, the restatement and control deficiency represent significant governance concerns.

    News flow: Balanced 51 → Balanced 47Gap Medium · 15 → Low · 0

    The filings read less positively.

    The gap closed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    KEMPER CorpKMPR

    8-K · Item 2.02 — Results of operations

    Q3 2026 net income of $52.4M ($0.88/share) vs. Q3 2025 loss of $21.0M ($-0.34/share). Adjusted operating income $59.9M ($1.01/share) vs. $20.4M ($0.33/share). Personal Auto profitability improved; California Combined Ratio improved 12 points since Q1 2026.

    Gap Low · 9 → Medium · 20

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Target Hospitality Corp.TH

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue up 30% YoY to $129.1M; Adjusted EBITDA up 59% to $34.2M with 480bps margin expansion. Since January, secured $1.7B in multi-year contracts representing 10,000+ beds. WHS segment revenue up 116% YoY. Company reaffirms full-year 2026 outlook and projects $750M+ revenue and $300M+ Adjusted EBITDA exiting 2027.

    Gap Low · 6 → Medium · 19

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Annexon, Inc.ANNX

    8-K · Item 2.02 — Results of operations

    Annexon reports Q3 2026 results with two late-stage registrational programs advancing: tanruprubart BLA submission anticipated Q4 2026 for GBS; vonaprument ARCHER II Phase 3 Month 15 endpoint assessment expected Q4 2026 for GA. Cash runway extended to 2028.

    Gap Very high · 53 → Very high · 61

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Onto Innovation Inc.ONTO

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $410M (+88% YoY, +19% QoQ) exceeded guidance high-end. Non-GAAP gross margin improved 60bps to 57.6%. Backlog exceeded $1.3B. Q4 guidance projects $430–450M revenue with strong margins. CEO cites robust AI/HPC demand.

    Gap Very high · 64 → Very high · 67

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Crescent Capital BDC, Inc.CCAP

    8-K · Item 2.02 — Results of operations

    Q3 2026 earnings: NII $0.37/share, net income $0.27/share, NAV $17.72. Board authorized $50M share repurchase; Sun Life plans additional $25M purchase. Q4 dividend declared at $0.34/share.

    Gap Very high · 50 → Very high · 62

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Definium Therapeutics, Inc.DFTX

    8-K · Item 2.02 — Results of operations

    Definium reported positive Phase 3 topline results for DT120 ODT in two GAD studies (Voyage and Panorama), met primary and key secondary endpoints with statistical significance. Received FDA Breakthrough Therapy Designation for MDD. DT402 showed positive Phase 2a results in ASD. Cash position strengthened to $1.05B.

    Gap High · 26 → High · 36

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Trevi Therapeutics, Inc.TRVI

    8-K · Item 2.02 — Results of operations

    Trevi initiated Phase 3 OCEAN-2 trial for IPF-related chronic cough; achieved FDA alignment on non-IPF ILD program with Phase 2 expected Q1 2027; received USPTO Notice of Allowance for patent covering nalbuphine ER dosing in hepatically impaired patients (expiring 2041); cash runway extended into 2030.

    Gap Medium · 16 → High · 28

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Novanta IncNOVT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 23% YoY to $305M; Adjusted EBITDA increased 38% to $80.3M with margin expansion of 290bps. Organic growth 9.9%. Customer bookings up 29% to $543M backlog. FY2026 guidance raised; 2027 revenue growth expected >15%.

    Recognition: Balanced 62 → Balanced 58Value: Watch 25 → Watch 31Gap Very high · 46 → Very high · 56

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    Ethan Allen Interiors IncETD

    8-K · Item 2.02 — Results of operations

    Q1 FY2027 net sales declined 12% YoY to $129.6M; operating margin compressed to 1.3% from 6.8% due to tariffs, lower traffic, and soft housing market. Adjusted EPS fell 77% to $0.10 from $0.43.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    QXO, Inc.QXO

    8-K · Item 2.02 — Results of operations

    QXO reported Q3 2026 preliminary results: net sales of $4.90B (up 79% YoY), GAAP net loss improved to $123M from $139M, and Adjusted EBITDA grew 85% to $557M. Growth driven by Kodiak and TopBuild acquisitions.

    Recognition: Balanced 53 → Balanced 56Value: Strong 74 → Balanced 62

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Tg Therapeutics, Inc.TGTX

    8-K · Item 2.02 — Results of operations

    TG Therapeutics raised full-year 2026 revenue guidance to ~$1B (from ~$950M) and BRIUMVI U.S. guidance to $915–920M (from $890–905M). Q3 revenue reached $260M. Positive clinical data presented including Phase 3 ENHANCE single-infusion results, Phase 1 subcutaneous bioavailability >60%, and seven-year efficacy follow-up.

    Recognition: Strong 71 → Strong 74Gap Low · 0 → Low · 8

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Bicara Therapeutics Inc.BCAX

    8-K · Item 2.02 — Results of operations

    Bicara achieved substantial enrollment in FORTIFI-HN01 pivotal trial for ficerafusp alfa in HPV-negative HNSCC, with interim results expected mid-2027. Cash runway extended to H1 2029. Commercial leadership team in place.

    Gap Low · 9 → Medium · 23

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Uniti Group Inc.UNIT

    8-K · Item 2.02 — Results of operations

    Uniti reported Q3 2026 results with record fiber premises constructed (162,000) and highest Kinetic net adds ever (~46,000). Fiber Infrastructure bookings of ~$1.9M MRR (second-highest on record, +20% YoY). Company raised full-year 2026 revenue guidance to $3,665–$3,695M and Adjusted EBITDA to $1,460–$1,490M.

    Gap High · 43 → Very high · 50

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Forward Air CorpFWRD

    8-K · Item 2.02 — Results of operations

    Forward Air reported Q3 2026 record revenue of $674M (+6.7% YoY), operating income of $44M (nearly tripled from $15M), and consolidated EBITDA of $101M (+30.7%). All three segments performed well; liquidity improved to $446M with lowest net leverage since Q1 2024.

    Recognition: Watch 39 → Balanced 47Gap Medium · 13 → Medium · 23

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Lucid Group, Inc.LCID

    8-K · Item 2.02 — Results of operations

    Lucid reported Q3 2026 revenue of $350M (up 4% YoY despite 41% market decline), reduced cash consumption 30% sequentially to $1.04B, and secured $1.75B liquidity increase from PIF. Company advancing on four Must-Win priorities including autonomy partnerships and AMP-2 Saudi facility.

    Value: Watch 32 → Watch 27Gap Very high · 63 → Very high · 67

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Groupon, Inc.GRPN

    8-K · Item 2.02 — Results of operations

    Q3 2026: Global revenue +2%, billings +6% YoY. Loss from continuing operations $0.8M (vs. $117.8M loss prior year). Adjusted EBITDA $14.7M. Company relaunched LivingSocial as agent-first marketplace and deployed FoundryAI platform.

    Recognition: Balanced 50 → Watch 44Value: Watch 31 → Watch 27

    Market attention has faded.

    The shares became dearer on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Praxis Precision Medicines, Inc.PRAX

    8-K · Item 2.02 — Results of operations

    Praxis reported Q3 2026 results with two lead programs under FDA review (relutrigine PDUFA Dec 27, ulixacaltamide PDUFA Jan 29), $1.3B cash runway into 2028, and advancing pipeline including EMERALD topline expected Q4 2026. Commercial teams hired for both programs.

    Recognition: Watch 35 → Watch 41Gap Low · 1 → Medium · 15

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Cannae Holdings, Inc.CNNE

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show portfolio transformation progress: $793M in noncore asset sales since early 2025, $22M additional investment in Black Knight Football, Exeter Rugby acquisition, $58.8M holding company expense reduction (70%), and $111M in share repurchases year-to-date representing 16.4% of shares outstanding.

    Gap Medium · 14 → High · 25

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026All industries

    Kodiak Gas Services, Inc.KGS

    8-K · Item 2.02 — Results of operations

    Kodiak reported Q3 2026 record Compression Infrastructure revenues of $318.4M and adjusted EBITDA of $224.5M (28.5% YoY growth). Company raised full-year 2026 Adjusted EBITDA guidance to $840–860M and discretionary cash flow to $580–600M. Power Infrastructure segment showed strong 75.2% adjusted margins.

    Gap Very high · 86 → Very high · 89

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Archer Aviation Inc.ACHR

    8-K · Item 2.02 — Results of operations

    Archer achieved FAA Market Survey Special Airworthiness Certificate for Midnight, enabling LA passenger operations. Boeing acquisition (Wisk, SkyGrid, Insitu) nearing close with only one approval outstanding. Expanded partnerships with Formula 1 and ITA Airways. Q3 adjusted EBITDA in line with guidance; $1.4B liquidity.

    Gap High · 35 → High · 44

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Sable Offshore Corp.SOC

    8-K · Item 2.02 — Results of operations

    Q3 2026: $154.4M revenue (+13% QoQ), 27k net bopd (+29% QoQ). Platform Hondo nearing online (Nov 2026, ~10k bopd forecast). Perf Add operations yielding +700 bopd per well. Diversified crude sales to 3 additional LA refineries after purchaser disruption.

    Gap Medium · 20 → High · 33

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    MBX Biosciences, Inc.MBX

    8-K · Item 2.02 — Results of operations

    MBX Biosciences initiated pivotal Phase 3 oPTimize trial for canvuparatide in hypoparathyroidism; MBX 4291 obesity candidate on track for Q4 2026 data; $481.6M cash runway into 2029; expanded leadership team.

    Gap Medium · 12 → Medium · 22

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Septerna, Inc.SEPN

    8-K · Item 2.02 — Results of operations

    Septerna reported Q3 2026 results with $565.2M cash runway into mid-2029. Key pipeline progress: SEP-479 Phase 1 data expected Q1 2027; SEP-204 selected as TSHR NAM candidate with Phase 1 initiation planned Q1 2027. R&D expenses increased 51% YoY; net loss of $26.6M vs. prior year income of $8.2M.

    Recognition: Balanced 61 → Balanced 57Gap Low · 5 → Medium · 15

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Xenon Pharmaceuticals Inc.XENE

    8-K · Item 2.02 — Results of operations

    Xenon submitted NDA for azetukalner in focal seizures to FDA (September 2026); completed X-NOVA2 enrollment with December 2026 topline data expected; initiated Phase 2 studies for pain programs XEN1701 and XEN1120; cash position $1.2B with runway into 2029.

    Gap Medium · 12 → Medium · 24

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Tango Therapeutics, Inc.TNGX

    8-K · Item 2.02 — Results of operations

    Tango reported promising Phase 1/2 data for vopimetostat plus daraxonrasib combination (82% ORR, 88% 9-month PFS in pancreatic cancer), plans Phase 3 initiation in H1 2027, and maintains $977.5M cash. R&D spending increased significantly.

    Recognition: Balanced 47 → Balanced 52Gap Very high · 49 → Very high · 53

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Ionis Pharmaceuticals IncIONS

    8-K · Item 2.02 — Results of operations

    Ionis lowered 2026 TRYNGOLZA product sales guidance from $100–110M to ~$50M due to slower-than-expected launch ramp, citing gradual establishment of new treatment paradigm. DAWNZERA and total revenue guidance reaffirmed.

    Value: Watch 30 → Watch 34Gap Medium · 19 → Low · 8

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Qualys, Inc.QLYS

    8-K · Item 2.02 — Results of operations

    Qualys reported Q3 2026 revenue of $188.0M (+11% YoY), net income of $57.2M (+14% YoY), and raised full-year 2026 revenue guidance to $736.9–$738.9M. Strong profitability metrics and product innovation drive confidence.

    Gap Low · 1 → Low · 6

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Orthofix Medical Inc.OFIX

    8-K · Item 2.02 — Results of operations

    Orthofix revised full-year 2026 guidance downward. Net sales guidance reduced from $845–855M to $825–830M; adjusted EBITDA guidance reduced from $95–100M to $86–88M. Weak U.S. Spine performance and near-term headwinds from operational restructuring cited.

    Gap Low · 5 → Low · 0

    Attention caught up with the documented progress.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Maze Therapeutics, Inc.MAZE

    8-K · Item 2.02 — Results of operations

    Maze completed enrollment in Phase 2 HORIZON trial of MZE829 exceeding targets with 50+ patients across three AMKD cohorts. Full data expected early 2027. Strong cash position of $477M supports runway into 2029. MZE782 enrollment ongoing with Phase 2 CKD trial planned for H1 2027.

    Gap Very high · 47 → Very high · 54

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Digital Turbine, Inc.APPS

    8-K · Item 2.02 — Results of operations

    Digital Turbine reported Q2 FY2027 revenue of $178.7M (+27% YoY), GAAP net income of $10.3M vs. prior-year loss, and non-GAAP adjusted EBITDA of $39.8M (+46% YoY). Both ODS and AGP segments grew 20%+ with strong operating leverage.

    Recognition: Balanced 57 → Balanced 54Gap Low · 0 → Low · 9

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Senseonics Holdings, Inc.SENS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $19.6M (+140% YoY) significantly exceeded expectations. Gross margin improved to 62%. Full-year guidance raised to $68–70M (+93–98% YoY) from $62–66M. U.S. revenue surged 160% YoY; EON Care network expanded to 100+ inserters.

    Recognition: Balanced 50 → Balanced 55Gap Low · 0 → Low · 4

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026All industries

    American Public Education IncAPEI

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue, net income, EPS, and adjusted EBITDA exceeded guidance. Health+ segment grew 9.0% YoY. Company raised full-year 2026 guidance across all key metrics. Institutional combination completed in August.

    Gap Medium · 15 → High · 30

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Structure Therapeutics Inc.GPCR

    8-K · Item 2.02 — Results of operations

    Structure Therapeutics reported Q3 2026 results with Phase 3 ACCOMPLISH trials for aleniglipron enrolling on schedule, positive Phase 2b extension data (16.2% weight loss), and $1.2B cash runway through 2028. R&D expenses increased significantly to support expanded clinical program.

    Gap High · 29 → High · 41

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    ArriVent BioPharma, Inc.AVBP

    8-K · Items 2.02, 5.02 — Results of operations

    FURVENT Phase 3 trial missed primary PFS endpoint (HR 0.75, p=0.0654). Lead R&D executive retiring. Partially offset by ADC pipeline progress and $393.2M cash runway to mid-2028.

    Gap High · 35 → Low · 2

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Ocular Therapeutix, IncOCUL

    8-K · Item 2.02 — Results of operations

    Ocular Therapeutix reports Q3 2026 results with AXPAXLI NDA submission on track for 4Q 2026 following positive Pre-NDA meeting. SOL-1 post-hoc analyses show sustained durability; SOL-R designed to exclude high-risk patients. Cash position of $530.6M supports runway into 2028.

    Gap Low · 5 → Medium · 16

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Sanmina CorpSANM

    8-K · Items 2.02, 8.01 — Results of operations

    Sanmina reported FY2026 revenue of $14.53B (+79% YoY), non-GAAP EPS of $13.28 (+100% YoY), and strong operating cash flow of $944M. Company raised FY2027 guidance to $17.5–$19.5B revenue (+27% midpoint) and $15.50–$17.50 non-GAAP EPS (+24% midpoint). Credit facility extended to 2031 with $70M incremental term loans.

    Value: Strong 72 → Strong 66

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.